What changed in Summit Therapeutics Inc.'s latest annual report
In the year ended 31 Dec 2025, Summit Therapeutics Inc.'s cash and cash equivalents rose 114.8% to USD 225.27m, from USD 104.86m; total liabilities rose 97.2% to USD 92.32m, from USD 46.81m; total assets rose 72.5% to USD 751.18m, from USD 435.56m.
Year ended 31 Dec 2025. Source: 10-K filed 23 Feb 2026, read it on SEC EDGAR.
USD 104.86m to USD 225.27m
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Net income | -221.31m | -1.08bn | Not comparable |
| Total assets | 435.56m | 751.18m | Up 72.5% |
| Total liabilities | 46.81m | 92.32m | Up 97.2% |
| Cash and cash equivalents | 104.86m | 225.27m | Up 114.8% |
| Shareholders' equity | 388.75m | 658.86m | Up 69.5% |
Questions people ask
Is Summit Therapeutics Inc. profitable?
Not in its latest year: it reported a net loss of USD 1.08bn in the year ended 31 Dec 2025. The year before: a net loss of USD 221.31m.
How much cash and debt does Summit Therapeutics Inc. have?
At its latest year end (31 Dec 2025), Summit Therapeutics Inc. reported cash and cash equivalents of USD 225.27m.
Where do these numbers come from?
From Summit Therapeutics Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Summit Therapeutics Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%